Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients

Background The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of t...

Descripción completa

Detalles Bibliográficos
Autores: Laplana Lafaja, Marina, Yuguero Torres, Oriol, Fibla Palazón, Joan
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/70104
Acceso en línea:https://doi.org/10.1371/journal.pone.0243598
http://hdl.handle.net/10459.1/70104
Access Level:acceso abierto
Palabra clave:Chloroquine
COVID-19 prevalence
Hydroxychloroquine
Prophylaxis
SARS-CoV-2
id ES_bc5105c4185537e158fbb6dcfbfe079a
oai_identifier_str oai:repositori.udl.cat:10459.1/70104
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patientsLaplana Lafaja, MarinaYuguero Torres, OriolFibla Palazón, JoanChloroquineCOVID-19 prevalenceHydroxychloroquineProphylaxisSARS-CoV-2Background The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age range and incidence region. COVID-19 disease prevalence was compared between treated and untreated-matched control sample. Results A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value = 0.027). Conclusion We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection measures as the general population.Public Library of Science2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1371/journal.pone.0243598http://hdl.handle.net/10459.1/70104reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésReproducció del document publicat a https://doi.org/10.1371/journal.pone.0243598Plos One, 2020, vol. 15, núm. 12, e0243598http://hdl.handle.net/10459.1/69488cc-by (c) Laplana, Marina et al., 2020info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:repositori.udl.cat:10459.1/701042026-06-24T12:42:17Z
dc.title.none.fl_str_mv Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
title Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
spellingShingle Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
Laplana Lafaja, Marina
Chloroquine
COVID-19 prevalence
Hydroxychloroquine
Prophylaxis
SARS-CoV-2
title_short Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
title_full Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
title_fullStr Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
title_full_unstemmed Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
title_sort Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients
dc.creator.none.fl_str_mv Laplana Lafaja, Marina
Yuguero Torres, Oriol
Fibla Palazón, Joan
author Laplana Lafaja, Marina
author_facet Laplana Lafaja, Marina
Yuguero Torres, Oriol
Fibla Palazón, Joan
author_role author
author2 Yuguero Torres, Oriol
Fibla Palazón, Joan
author2_role author
author
dc.subject.none.fl_str_mv Chloroquine
COVID-19 prevalence
Hydroxychloroquine
Prophylaxis
SARS-CoV-2
topic Chloroquine
COVID-19 prevalence
Hydroxychloroquine
Prophylaxis
SARS-CoV-2
description Background The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age range and incidence region. COVID-19 disease prevalence was compared between treated and untreated-matched control sample. Results A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value = 0.027). Conclusion We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection measures as the general population.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1371/journal.pone.0243598
http://hdl.handle.net/10459.1/70104
url https://doi.org/10.1371/journal.pone.0243598
http://hdl.handle.net/10459.1/70104
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1371/journal.pone.0243598
Plos One, 2020, vol. 15, núm. 12, e0243598
http://hdl.handle.net/10459.1/69488
dc.rights.none.fl_str_mv cc-by (c) Laplana, Marina et al., 2020
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Laplana, Marina et al., 2020
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418102768271360
score 15,812429

Similares en LA Referencia